Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience
Jérémy Baude et al, 2024, Cancers CrossRef
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Benedikt Feuerecker et al, 2021, European Urology CrossRef
Etoposide Loaded SPION‐PNIPAM Nanoparticles Improve the in vitro Therapeutic Outcome on Metastatic Prostate Cancer Cells via Enhanced Apoptosis
Merve Erkisa et al, 2020, Chemistry & Biodiversity CrossRef
DNA‐PKc inhibition overcomes taxane resistance by promoting taxane‐induced DNA damage in prostate cancer cells
Olivia S. Chao et al, 2021, The Prostate CrossRef
Delineating the tumour-regulatory roles of EYA4
Zhi Xiong Chong et al, 2023, Biochemical Pharmacology CrossRef
A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing
Hiroshi Hongo et al, 2021, International Cancer Conference Journal CrossRef
Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy
Keitaro Watanabe et al, 2019, Clinical Genitourinary Cancer CrossRef
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Benedikt Feuerecker et al, 2023, Journal of Nuclear Medicine CrossRef
Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment
Norman J. Maitland et al, 2019, Human Cell Transformation CrossRef
Current concepts of neuroendocrine cancer of the prostate: a clinical case and review of the literature
Grigoriy A. Chizh et al, 2022, Journal of Modern Oncology CrossRef
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Abir Salwa Ali et al, 2018, Medical Oncology CrossRef